• CSPC Pharmaceutical Group announced Oct. 30, 2026, that its Phase I/II SYS6043 trial began at its first Chinese center for advanced solid tumors.
• The B7-H3-targeting antibody-drug conjugate received Chinese regulatory clearance for clinical testing in September 2026.
• The study will evaluate safety, tolerability and preliminary efficacy, testing SYS6043 alone or with bevacizumab and/or chemotherapy.
• Patient recruitment and screening are underway; no clinical results were presented in the announcement.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CSPC Pharmaceutical Group Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261030-12390826), on October 30, 2026, and is solely responsible for the information contained therein.